Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial

Khonche, Ahmad; Biglarian, Omid; Panahi, Yunes; Valizadegan, Ghasem; Soflaei, Sara Saffar; Ghamar-Chehreh, Mohammad Ebrahim; Majeed, Muhammed; Sahebkar, Amirhossein

doi:10.1055/s-0042-109394

Cited by 47 publications

(40 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Curcumin is a yellow phenolic compound that was initially isolated from Curcuma longa L. (turmeric) rhizomes in 1 815 [10]. Curcumin has been shown to possess numerous pharmacological effects including antioxidant, anticarcinogenic, anti-inflammatory, antidepressant, lipid-modifying, anti-arthritic, properties have been described for this polyphenol [11][12][13][14][15][16][17][18][19][20][21][22][23]. Numerous pharmaco-dietary polyphenol with lipid-modifying, antioxidant and anti-inflammatory properties.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

et al. 2017

View full text Add to dashboard Cite

Objective Non-alcoholic fatty liver disease (NAFLD) is a common liver disease characterized by excess lipid deposition in the hepatic tissue and subsequent oxidative and inflammatory damage. Curcumin is a dietary polyphenol with lipid-modifying, antioxidant and anti-inflammatory properties. This study aimed to evaluate the efficacy and safety of supplementation with phytosomal curcumin in subjects with NAFLD.Methods Patients diagnosed with NAFLD (grades 1-3 according to liver ultrasonography) were randomly assigned to the curcumin (phytosomal form; 1 000 mg/day in 2 divided doses) (n = 50) or placebo group (n = 52) for a period of 8 weeks. All patients received dietary and lifestyle advises before the start of trial. Anthropometric measurements, hepatic enzymes, and liver ultrasonography were assessed at baseline and after 8 weeks of follow-up.Results 87 subjects (n = 44 and 43 in the curcumin and control group, respectively) completed the trial. Supplementation with curcumin was associated with a reduction in body mass index ( − 0.99 ± 1.25 vs.− 0.15 ± 1.31 in the curcumin and placebo groups, respectively; p = 0.003) and waist circumference ( − 1.74 ± 2.58 vs. − 0.23 ± 3.49 in the curcumin and placebo groups, respectively; p = 0.024). Ultrasonographic findings were improved in 75.0 % of subjects in the curcumin group, while the rate of improvement in the control group was 4.7 % (p < 0.001).Serum levels of aspartate aminotransferase and alanine aminotransferase were reduced by the end of trial in the curcumin group (p < 0.001) but elevated in the control group (p < 0.001). Curcumin was safe and well tolerated during the course of trial.Conclusion Short-term supplementation with curcumin improves liver fat and transaminase levels in patients with NAFLD.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A trial in 2007 found that taking a 2-g Curcuma longa capsule daily for four weeks indicated no significant difference with ranitidine for dyspepsia relief 23 . A later study in 2016 showed that addition of curcumin on top of the standard anti-helicobacter regimen in patients with peptic ulcers was safe and improved symptoms of dyspepsia but did not enhance effect on the eradication of Helicobacter pylori infection 24 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial

2019

View full text Add to dashboard Cite

Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa, 26 in 1500 mg Curcuma longa, and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001.

show abstract

“…Then different volume curcumin solutions were added into PNBCDs solution drop by drop and a series of calculated concentration (0, 0.2, 0.5, 0.7, 1, 1. 5,3,5,6,7,8,9,10,12,14,16,18,20,30,40,50,60,70,80,90, 100, 120 mM) were prepared. Aer solution mixed to equilibrium, the PL spectra were recorded (l ex ¼ 311 nm) when PL emission maintained stabilization.…”

Section: Determination Of Curcumin With Pnbcds Based Uorescent Nanosmentioning

confidence: 99%

“…As a biologically active constituent of turmeric, 1 curcumin exhibits diverse biological and pharmacological activities such as anti-inammatory, 2 antibacterial, 3 hepatoprotective, 4 anticarcinogenic, 5 antioxidant 6,7 and antidyspeptic 8 properties. As a result, curcumin has been widely applied in pharmacology for many years.…”

Section: Introductionmentioning

confidence: 99%

Highly photoluminescent and temperature-sensitive P, N, B-co-doped carbon quantum dots and their highly sensitive recognition for curcumin

Liu

Shi

et al. 2019

RSC Adv.

View full text Add to dashboard Cite

show abstract

Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial

Abstract: Addition of curcumin on top of the standard anti-helicobacter regimen in patients with PU is safe and improves dyspepsia symptoms but has no enhancing effect on the eradication of H. pylori infection.

Cited by 47 publications

References 39 publications

Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial

Highly photoluminescent and temperature-sensitive P, N, B-co-doped carbon quantum dots and their highly sensitive recognition for curcumin

Contact Info

Product

Resources

About